Argenta and Dr Reddy’s reach milestone in respiratory disease
Argenta CEO Dr Christopher Ashton said: “Just 18 months after signing the deal with Dr Reddy’s, the team has already selected the first candidate drug to proceed into

Argenta CEO Dr Christopher Ashton said: “Just 18 months after signing the deal with Dr Reddy’s, the team has already selected the first candidate drug to proceed into

The agreement secures the supply of AX200 far beyond the clinical development and provides a solid basis for the envisaged marketing of the compound. Sygnis successfully completed a

The kit contains Rosula Clarifying Wash (sodium sulfacetamide 10% and sulfur 4%) in a urea vehicle, and A-FIL Cream (meradimate 5% and titanium dioxide 5%) sunscreen. Rosula Clarifying

Simcere said that through this transaction it has acquired the market-leading chemotherapeutic drug Jiebaisu and is enriching its anticancer product portfolio. In addition, it has acquired a specialized

The results of the Phase I trials show that when topically applied to the anterior nares (the lower nasal passages), NVC-422 appears safe and well tolerated, with undetectable

This trial represents the first clinical trial in which a monoclonal antibody (MAb) targeting granulocyte-macrophage colony stimulating factor receptor (GM-CSFR) is being investigated in this population. MedImmune currently

In the US, the tablet is sold under the trade name Zolinza (vorinostat). If approved, the centralized filing of this application would allow Merck Sharp & Dohme (MSD)

The parties have agreed to work together to sign a definitive agreement within 30 days and to close the acquisition transaction within 60 days of the signing. Under

The purchasers in the transaction include previous investor General Electric Pension Trust and new investor Corriente Master Fund. In addition, the company has issued warrants to purchase approximately

Torisel (temsirolimus) specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival. Robert Ruffolo, Jr., president of Wyeth